Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis
- 4 September 2017
- journal article
- review article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 37 (11) , 1009-1023
Abstract
Interferon-free regimens are rapidly evolving for patients with chronic hepatitis C virus (HCV) infection. We performed this meta-analysis to investigate the safety and efficacy of a combination regimen (ombitasvir [OBV]/paritaprevir [PTV]/ritonavir [r] ± dasabuvir [DSV]) for the treatment of patients with HCV genotype 1 infection.Keywords
This publication has 34 references indexed in Scilit:
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with CirrhosisNew England Journal of Medicine, 2014
- Hepatitis C virus therapy in the direct acting antiviral eraCurrent Opinion in Gastroenterology, 2014
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinNew England Journal of Medicine, 2014
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinNew England Journal of Medicine, 2014
- Hepatitis C virus: Here comes all-oral treatmentCleveland Clinic Journal of Medicine, 2014
- All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naïve Patients With Genotype 1 HCV InfectionHepatology, 2014
- Current and Future Therapies for Hepatitis C Virus InfectionNew England Journal of Medicine, 2013
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHepatology, 2013
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Hepatitis C Virus Infection and Hepatocellular CarcinomaClinics in Liver Disease, 2008